Your browser is no longer supported. Please, upgrade your browser.
ARTL Artelo Biosciences, Inc. daily Stock Chart
Artelo Biosciences, Inc.
Index- P/E- EPS (ttm)-0.37 Insider Own15.50% Shs Outstand3.18M Perf Week-10.38%
Market Cap6.04M Forward P/E- EPS next Y-2.11 Insider Trans- Shs Float2.36M Perf Month-17.03%
Income-2.00M PEG- EPS next Q-0.51 Inst Own- Short Float0.37% Perf Quarter-48.51%
Sales- P/S- EPS this Y-752.40% Inst Trans- Short Ratio0.45 Perf Half Y68.14%
Book/sh0.07 P/B27.14 EPS next Y-35.30% ROA-366.70% Target Price8.00 Perf Year-
Cash/sh0.09 P/C20.14 EPS next 5Y- ROE690.70% 52W Range0.80 - 5.00 Perf YTD65.22%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-58.34% Beta-
Dividend %- Quick Ratio1.10 Sales past 5Y- Gross Margin- 52W Low160.37% ATR0.27
Employees1 Current Ratio1.10 Sales Q/Q- Oper. Margin- RSI (14)48.41 Volatility16.46% 13.88%
OptionableNo Debt/Eq0.00 EPS Q/Q-269.40% Profit Margin- Rel Volume0.62 Prev Close1.90
ShortableYes LT Debt/Eq0.00 EarningsOct 21 BMO Payout- Avg Volume19.43K Price2.08
Recom2.00 SMA201.45% SMA50-8.47% SMA20010.59% Volume5,836 Change9.63%
Sep-18-19 08:00AM  Artelo Biosciences Cannabidiol (CBD) Studies Referenced in September Issue of Nature Medicine GlobeNewswire
Sep-11-19 09:00AM  Artelo Biosciences to Present at the Fall Investor Summit in New York City on September 17th ACCESSWIRE +7.29%
Sep-04-19 01:34PM  What Percentage Of Artelo Biosciences, Inc. (NASDAQ:ARTL) Shares Do Insiders Own? Simply Wall St.
Jul-15-19 04:01PM  Artelo Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Jul-10-19 07:23AM  Cannabis stocks dragged down by CannTrusts losses after cannabis seizure MarketWatch -8.10%
Jun-25-19 01:00PM  Artelo Biosciences Announces Closing of $8.0 Million Public Offering and Partial Exercise and Closing of Over-Allotment Option GlobeNewswire -6.69%
May-08-19 04:05PM  Artelo Biosciences Retains Crescendo Communications, LLC for Investor Relations Services ACCESSWIRE
Jan-03-19 07:00AM  Artelo Biosciences Retains Maxim Group LLC to Provide Financial Advisory and Investment Banking Services ACCESSWIRE
Oct-09-18 08:00AM  New Preclinical Cell-Line Data of Artelo Biosciences' ART27.13 Demonstrate Anti-Proliferative Activity in Tumor Models ACCESSWIRE
Jul-03-18 08:00AM  Artelo Biosciences Announces Five Year Commitment To Sponsor The Young Investigator Award At The International Cannabinoid Research Society Annual Symposium PR Newswire
Artelo Biosciences, Inc., an ethical biopharmaceutical company, focuses on developing, licensing, and commercializing cannabinoid therapeutic treatments. Its products pipeline includes ART12.11, a cannabidiol composition for the treatment of inflammatory bowel disease, stroke, and rare/orphan diseases; ART26.12, an endocannabinoid transport protein (FABP5) inhibitor for the treatment of breast cancer, prostate cancer, and neuropathic and nociceptive pain; and ART27.13 for the treatment of cancer and cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was founded in 2011 and is based in La Jolla, California.